home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Corel Medical Series: Cancer
/
Corel Medical Series: Cancer.iso
/
mac
/
Program
/
c06.dxr
/
00196_Field_SRC.c06.A.42.txt
< prev
next >
Wrap
Text File
|
1997-01-28
|
988b
|
15 lines
or removal of the ovaries for premenopausal patients, and progestins , androgens , Cytadren , estrogens or
tamoxifen for postmenopausal patients. Hormonal manipulation may be especially useful for those with
predominantly bone metastases.
• If metastases involve vital organs or are life-threatening, chemotherapy combinations similar to those used in
earlier stages are given. Again, the risk of Adriamycin-induced cardiac toxicity may limit the amount of drug
that can be given.
Five-Year Survival 10 percent
Investigational
• All patients are candidates for clinical trials , which may involve new drugs in Phase I, II or III trials, new
biologic agents, autologous bone marrow transplantation (ABMT), treatment with monoclonal antibodies , or
high-dose chemotherapy with growth factor (such as G-CSF) support. The use of ABMT for advanced
disease shows some early promise (20-25 percent after two years) but the final role of ABMT is uncertain.